Citius Pharmaceuticals (CTXR) Other Non-Current Assets (2014 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Other Non-Current Assets came in at $38062.0 in Q1 2026, down 99.96% YoY from $102.2 million in Q1 2025, and little changed on a QoQ basis from $38062.0 in Q4 2025.
Citius Pharmaceuticals (CTXR) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 13 years of Other Non-Current Assets data on file, last reported at $38062.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 99.96% year-over-year to $38062.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38062.0 (down 99.96% YoY) and the FY2025 annual result came in at $38062.0, down 99.96% from the prior year.
- Other Non-Current Assets was little changed at $38062.0 in Q1 2026, from $38062.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $102.2 million in Q4 2024 to a low of $38062.0 in Q2 2022.
- A 5-year average of $35.5 million and a median of $38062.0 in 2022 frame the typical range for Other Non-Current Assets.
- The widest YoY moves for Other Non-Current Assets: up 268369.49% in 2025, down 99.96% in 2025.
- Tracing CTXR's Other Non-Current Assets over 5 years: stood at $38062.0 in 2022, then surged by 155961.16% to $59.4 million in 2023, then soared by 72.03% to $102.2 million in 2024, then slumped by 99.96% to $38062.0 in 2025, then changed by 0.0% to $38062.0 in 2026.
- The last three Other Non-Current Assets figures came in at $38062.0 (Q1 2026), $38062.0 (Q4 2025), and $38062.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Citius Pharmaceuticals | 15.60 Mn | 15.60 Mn | 1.00 Mn | 98.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38,062.00 |
| Dec 31, 2025 | 38,062.00 |
| Sep 30, 2025 | 38,062.00 |
| Jun 30, 2025 | 38,062.00 |
| Mar 31, 2025 | 102.18 Mn |
| Dec 31, 2024 | 102.18 Mn |
| Sep 30, 2024 | 92.80 Mn |
| Jun 30, 2024 | 38,062.00 |
| Mar 31, 2024 | 38,062.00 |
| Dec 31, 2023 | 59.40 Mn |
| Sep 30, 2023 | 59.40 Mn |
| Jun 30, 2023 | 38,062.00 |
| Mar 31, 2023 | 68.78 Mn |
| Dec 31, 2022 | 38,062.00 |
| Sep 30, 2022 | 59.40 Mn |
| Jun 30, 2022 | 38,062.00 |
| Mar 31, 2022 | 59.40 Mn |
| Dec 31, 2021 | 68.78 Mn |
| Sep 30, 2021 | 38,062.00 |
| Jun 30, 2021 | 19.40 Mn |